Bicara Therapeutics

Company snapshot

Bicara Therapeutics is a clinical-stage biotech company pioneering bifunctional antibodies for targeted tumor modulation. Founded in 2020, we've built a global team of over 100 employees headquartered in Boston, with a clear focus on advancing our lead asset, ficerafusp alfa, or FICERA - a potentially first-in-class bifunctional EGFR-directed antibody combined with a TGF-β ligand trap. Our innovat

• 6 active pipeline program(s) linked via ClinicalTrials.gov.
• 6 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Bicara Therapeutics. Not investment advice.

• Peer + 0 momentum

  Inhibrx Biosciences

  TA overlap score 22

Recent activity

Latest pipeline, patent, and corporate events for Bicara Therapeutics.

1. Jun 8, 2026 Clinical update

   BCA101X301 — Phase 3

2. May 26, 2026 Clinical update

   Ficerafusp alfa — Phase 3

3. May 23, 2026 Clinical update

   Ficerafusp alfa — Phase 2

4. May 23, 2026 Clinical update

   Ficerafusp alfa — Phase 2

5. May 23, 2026 Clinical update

   Pembrolizumab — Phase 2

View all clinical trial activity →

• What is Bicara Therapeutics?

  Bicara Therapeutics is a pharma organization headquartered in Boston, USA. It trades on NYSE under ticker BCAX. Primary therapeutic focus areas include Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent or Metastatic Head and Neck S

• Is Bicara Therapeutics publicly traded?

  Yes. Bicara Therapeutics is listed with ticker BCAX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Bicara Therapeutics develop or market?

  We link 4 drug profile(s) where Bicara Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/bicara-therapeutics#company-drugs.

• What are the latest developments for Bicara Therapeutics?

  In the last 12 months our linked public records show 6 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Bicara Therapeutics focus on?

  Bicara Therapeutics focuses on Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. based on our analysis of their pipeline programs and drug development activities.